An Open, Randomized, Single-Center, Crossover Pharmacokinetic Study of Meropenem after Intraperitoneal and Intravenous Administration in Patients Receiving Automated Peritoneal Dialysis
Open Access
- 1 May 2016
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 60 (5) , 2790-2797
Abstract
The objective of this study was to determine the pharmacokinetic profile of meropenem in automated peritoneal dialysis (APD) patients. In 6 patients without peritonitis, a single dose of 0.5 g of meropenem was applied intraperitoneally (i.p.) or intravenously (i.v.) and concentrations in serum and dialysate were measured at specified intervals over 24 h with high-performance liquid chromatography-mass spectrometry. The mean maximum concentrations of meropenem in serum ( C max ) were 27.2 mg/liter (standard deviation [SD], ±6.9) and 10.1 mg/liter (SD, ±2.5) and in dialysate were 3.6 mg/liter (SD, ±2.3) and 185.8 mg/liter (SD, ±18.7) after i.v. and i.p. administrations, respectively. The mean areas under the curve from 0 to 24 (AUC 0–24 ) of meropenem in serum were 173.5 mg · h/liter (SD, ±29.7) and 141.4 mg · h/liter (SD, ±37.5) ( P = 0.046) and in dialysate were 42.6 mg · h/liter (SD, ±20.0) and 623.4 mg · h/liter (SD, ±84.1) ( P = 0.028) after i.v. and i.p. administrations, respectively. The ratios for dialysate exposure over plasma exposure after i.v. and i.p. treatments were 0.2 (SD, ±0.1) and 4.6 (SD, ±0.9), respectively ( P = 0.031). A mean target value of 40% T >MIC (time for which the free meropenem concentration exceeds the MIC) for clinically relevant pathogens with EUCAST susceptibility breakpoints of 2 mg/liter was reached in serum after i.p. and i.v. administrations and in dialysate after i.p. but not after i.v. administration. The present data indicate that low i.p. exposure limits the i.v. use of meropenem for PD-associated peritonitis. In contrast, i.p. administration not only results in superior concentrations in dialysate but also might be used to treat systemic infections.Keywords
This publication has 18 references indexed in Scilit:
- Pharmacokinetics of Intraperitoneal and Intravenous Fosfomycin in Automated Peritoneal Dialysis Patients without PeritonitisAntimicrobial Agents and Chemotherapy, 2012
- Consensus Guidelines for the Prevention and Treatment of Catheter-Related Infections and Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis: 2012 UpdatePeritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 2012
- Peritoneal Dialysis-Related Infections Recommendations: 2010 UpdatePeritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 2010
- Intraperitoneal Meropenem Administration: A Possible Alternative to the Intravenous RoutePeritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 2010
- Clinical Practice Guidelines for Peritoneal Adequacy, Update 2006American Journal of Kidney Diseases, 2006
- Disposition of Ceftazidime After Intraperitoneal Administration in Adolescent Patients Receiving Continuous Cycling Peritoneal DialysisAmerican Journal of Kidney Diseases, 2006
- The Pharmacodynamics of β‐LactamsClinical Infectious Diseases, 1998
- Intraperitoneal penetration of meropenemJournal of Antimicrobial Chemotherapy, 1991
- Teicoplanin pharmacokinetics in patients undergoing continuous ambulatory peritoneal dialysis after intravenous and intraperitoneal dosingAntimicrobial Agents and Chemotherapy, 1989
- Drug Therapy in Patients Undergoing Peritoneal Dialysis Clinical Pharmacokinetic ConsiderationsClinical Pharmacokinetics, 1985